Phaseline

Companies › JT International

JT International: clinical trials, targets and expected readouts

1 active drug program in 29 registered trials: 16 Phase 4, 5 Phase 3, 5 Phase 2, 3 Phase 1; Infectious disease, Oncology, Other, Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nicotine
Neuronal acetylcholine receptor; alpha4/beta2 agonist
CHRNB2, CHRNA4Phase 1Smoking Behaviors; Nicotine Dependence; Tobacco Use Disorder; Tobacco …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07476144NicotinePhase 1Smoking BehaviorsOtherJul 2026
NCT05233228NicotinePhase 2Cigarette SmokingOtherAug 2026
NCT04176172NicotinePhase 3HIV/AIDSInfectious diseaseNov 2026
NCT05515354NicotinePhase 4Nicotine DependencePsychiatryDec 2026
NCT07585006NicotinePhase 1Tobacco-Related CarcinomaOncologyDec 2026
NCT05722561NicotinePhase 2Opioid Use DisorderPsychiatryMar 2027
NCT05587361NicotinePhase 4Tobacco Use DisorderPsychiatryMar 2027
NCT06832085NicotinePhase 4TobaccoOtherApr 2027
NCT06832098NicotinePhase 3Vaping CessationOtherApr 2027
NCT05513872NicotinePhase 1Tobacco UsePsychiatryAug 2027
NCT03315910NicotinePhase 4Smoking CessationOtherOct 2027
NCT03315910NicotinePhase 4Smoking CessationOtherOct 2027
NCT05723588NicotinePhase 2Tobacco Use DisorderPsychiatryNov 2027
NCT07503925NicotinePhase 4Tobacco-Related CarcinomaOncologyDec 2027
NCT07503925NicotinePhase 4Tobacco-Related CarcinomaOncologyDec 2027
NCT06315881NicotinePhase 2Tobacco-Related CarcinomaOncologyJan 2028
NCT06598397NicotinePhase 4Human Immunodeficiency Virus (HIV)Infectious diseaseJun 2028
NCT06474299NicotinePhase 4Smoking CessationOtherJul 2028
NCT06630728NicotinePhase 4Smoking (Tobacco) AddictionPsychiatryDec 2028
NCT06630728NicotinePhase 4Smoking (Tobacco) AddictionPsychiatryDec 2028
NCT06595459NicotinePhase 4SmokerOtherJan 2029
NCT06595459NicotinePhase 4SmokerOtherJan 2029
NCT07099638NicotinePhase 2Smoking CessationOtherJun 2029
NCT07095205NicotinePhase 4Major Depressive Disorder (MDD)PsychiatrySep 2029
NCT05154669NicotinePhase 3SmokingOtherDec 2029
NCT05154669NicotinePhase 3SmokingOtherDec 2029
NCT05154669NicotinePhase 3SmokingOtherDec 2029
NCT07419425NicotinePhase 4Smoking CessationOtherJan 2030
NCT07089901NicotinePhase 4SmokingOtherMar 2030

Targets

CHRNB2 (1) CHRNA4 (1)

Companies with the same targets

McNeil

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.